Collectively, these findings demonstrate microglial cGAS promote neuroinflammation and neurodegeneration during the progression of MPTP‐induced PD mouse models and suggest cGAS may serve as a therapeutic target for PD patients. The gene discussed is CGAS; the disease is Parkinson disease.